Opportunistic infections associated with TNF-α treatment

Robert Orenstein, Eric L. Matteson

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The therapeutic agents known as TNF-α inhibitors have been widely adopted as effective and standard therapy for many rheumatic diseases. Since their introduction into clinical practice, there has been concern that these agents that blunt host immunity to intracellular pathogens would lead to the development of opportunistic infections. Early reports of extrapulmonary tuberculosis, listeriosis, Pneumocystis jiroveci pneumonia and invasive fungal diseases seemed to confirm this association. Prospective and retrospective studies, registries, adverse reporting databases and experience from clinical practices indicate at least a twofold risk of serious bacterial infections with TNF3 versus standard DMARDs but data are limited on opportunistic infections (Ols). This article will review the available data on Ols describing these risks and studies that have been done to reduce that risk.

Original languageEnglish (US)
Pages (from-to)567-576
Number of pages10
JournalFuture Rheumatology
Volume2
Issue number6
DOIs
StatePublished - Dec 1 2007

Keywords

  • Adalimumab
  • Etanercept
  • Infliximab
  • Opportunistic infections
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Opportunistic infections associated with TNF-α treatment'. Together they form a unique fingerprint.

Cite this